There is growing usage of GLP-1, with some reports indicating a significant portion of the US population is now using these drugs for weight loss. The increased use of GLP-1 has been linked to a drop in the US obesity rate, and medicare has introduced new coverage for these medications. The role and impact of GLP-1 are being explored in various contexts, including its potential effects on behavior and its market trends.